Bezafibrate and medroxyprogesterone acetate target resting and CD40L-stimulated primary marginal zone lymphoma and show promise in indolent B-cell non-Hodgkin lymphomas

References

• Harris NL, Jaffe ES, Stein H, et al. Lymphoma classification proposal: clarification. Blood 1995;85:857–860.
   PubMed Web of Science ®Google Scholar
• Kuppers R, Klein U, Hansmann ML, et al. Cellular origin of human B-cell lymphomas. N Engl J Med 1999;341:1520–1529.
   PubMed Web of Science ®Google Scholar
• Castillo R, Mascarenhas J, Telford W, et al. Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4. Leukemia 2000;14:292–298.
   PubMed Web of Science ®Google Scholar
• Williams ME, Dreyling M, Winter J, et al. Management of mantle cell lymphoma: key challenges and next steps. Clin Lymphoma Myeloma Leuk 2010;10:336–346.
   PubMed Web of Science ®Google Scholar
• Hayden RE, Pratt G, Roberts C, et al. Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches. Leuk Lymphoma 2012;53:537–549.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Cignetti A, Granziero L, et al. Chronic lymphocytic leukaemia: a model for investigating potential new targets for the therapy of indolent lymphomas. Best Pract Res Clin Haematol 2002;15:563–575.
   PubMed Web of Science ®Google Scholar
• Gordon J, Pound JD. Fortifying B cells with CD154: an engaging tale of many hues. Immunology 2000;100:269–280.
   PubMed Web of Science ®Google Scholar
• Clodi K, Snell V, Zhao S, et al. Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Br J Haematol 1998;103:217–219.
   PubMed Web of Science ®Google Scholar
• Fiumara P, Younes A. CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies. Br J Haematol 2001;113:265–274.
   PubMed Web of Science ®Google Scholar
• Homig-Holzel C, Hojer C, Rastelli J, et al. Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med 2008;205: 1317–1329.
   PubMed Web of Science ®Google Scholar
• Buske C, Gogowski G, Schreiber K, et al. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand. Exp Hematol 1997;25:329–337.
   PubMed Web of Science ®Google Scholar
• Martin I, Bonnefoix T, Roucard C, et al. Role of autologous CD4 + T cell clones in human B non-Hodgkin’s lymphoma: aborted activation and G1 blockade induced by cell-cell contact. Eur J Immunol 1999;29:3188–3195.
   PubMed Web of Science ®Google Scholar
• Visser HP, Tewis M, Willemze R, et al. Mantle cell lymphoma proliferates upon IL-10 in the CD40 system. Leukemia 2000;14:1483–1489.
   PubMed Web of Science ®Google Scholar
• Hilchey SP, Rosenberg AF, Hyrien O, et al. Follicular lymphoma tumor-infiltrating T-helper (T(H)) cells have the same polyfunctional potential as normal nodal T(H) cells despite skewed differentiation. Blood 2011;118:3591–3602.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Fisher RI. Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol 2011;29:1876–1884.
   PubMed Web of Science ®Google Scholar
• Habermann TM. New developments in the management of diffuse large B-cell lymphoma. Hematology 2012;17:S93–S97.
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3’-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603–3612.
   PubMed Web of Science ®Google Scholar
• Alinari L, Christian B, Baiocchi RA. Novel targeted therapies for mantle cell lymphoma. Oncotarget 2012;3:203–211.
   PubMedGoogle Scholar
• Kahl BS, Cheson BD, Friedberg JW. Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. Clin Adv Hematol Oncol 2010;8:1–16.
   PubMedGoogle Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591–594.
   PubMed Web of Science ®Google Scholar
• Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012;119:1182–1189.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Furman M, Winer ES. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 2012;21:15–22.
   PubMed Web of Science ®Google Scholar
• Fenton SL, Luong QT, Sarafeim A, et al. Fibrates and medroxyprogesterone acetate induce apoptosis of primary Burkitt’s lymphoma cells and cell lines: potential for applying old drugs to a new disease. Leukemia 2003;17:568–575.
   PubMed Web of Science ®Google Scholar
• Molyneux E, Merrick B, Khanim FL, et al. Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497). Br J Haematol 2014;164:888–890.
   PubMed Web of Science ®Google Scholar
• Hayden RE, Pratt G, Drayson MT, et al. Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance. Haematologica 2010;95:1889–1896.
   PubMed Web of Science ®Google Scholar
• Gagro A, McCloskey N, Challa A, et al. CD5-positive and CD5-negative human B cells converge to an indistinguishable population on signalling through B-cell receptors and CD40. Immunology 2000;101:201–209.
   PubMed Web of Science ®Google Scholar
• Hayden RE, Pratt G, Davies NJ, et al. Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2. Leukemia 2009;23: 292–304.
   PubMed Web of Science ®Google Scholar
• Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program 2005:307–313.
   Google Scholar
• Vogler M, Butterworth M, Majid A, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009;113:4403–4413.
   PubMed Web of Science ®Google Scholar
• Khanim FL, Hayden RE, Birtwistle J, et al. Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS One 2009;4:e8147.
   PubMed Web of Science ®Google Scholar
• Epron G, Ame-Thomas P, Le Priol J, et al. Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia 2012;26:139–148.
   PubMed Web of Science ®Google Scholar
• Craig VJ, Cogliatti SB, Arnold I, et al. B-cell receptor signaling and CD40 ligand-independent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis. Leukemia 2010;24:1186–1196.
   PubMed Web of Science ®Google Scholar
• Voorzanger-Rousselot N, Favrot M, Blay JY. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 1998;92:3381–3387.
   PubMed Web of Science ®Google Scholar
• Gribben J, Rosenwald A, Gascoyne R, Lenz G. Targeting the microenvironment. Leuk Lymphoma 2010;51(Suppl. 1):34–40.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078–2088.
   PubMed Web of Science ®Google Scholar
• Meadows SA, Vega F, Kashishian A, et al. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012;119:1897–1900.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J, et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 2008;113:1933–1952.
   PubMed Web of Science ®Google Scholar
• Drummond MW, Holyoake TL. Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good? Blood Rev 2001;15:85–95.
   PubMed Web of Science ®Google Scholar
• Murray JA, Khanim FL, Hayden RE, et al. Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). Br J Haematol 2010;149:65–69.
   PubMed Web of Science ®Google Scholar